Palliative treatment for advanced non-small cell lung cancer

Hematology/Oncology Clinics of North America

Volumn 18, Issue 1, 2004, Pages 115-130

  MacBeth, Fergus ^a   Stephens, Richard ^b  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b Med Res Cncl Clinical Trials Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; TENIPOSIDE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; DECISION MAKING; HOSPITALIZATION; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 1042275573     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00140-0     Document Type: Review

References (50)

1. Hansen H. Textbook of lung cancer. 2002;Martin Dunitz, London.
2. Diagnosis and management of lung cancer: ACCP evidence-based guidelines. Chest. 123(Suppl 1):2003.
3. Macbeth F., Toy E., Coles B., Melville A., Eastwood A. Palliative radiotherapy regimens for non small cell lung cancer. Cochrane Library, issue 4. 2003;John Wiley and Co. Chichester, UK.
4. Palliative care. Available at: http://www.who.int/cancer/palliative/en. Accessed November 10, 2003.
5. Sneeuw K.C.A., Aaronson N.K., Sprangers M.A.G., Detmar S.B., Wever L.D.V., Schornagel J.H. Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses. Br J Cancer. 81:1999;87-94.
6. Taylor A.E., Olver I.N., Sivanathan T., Chi M., Purnell C. Observer grading performance status in cancer patients. Support Care Cancer. 795:1999;332-335.
7. Ando M., Ando Y., Hasegawa Y., Shimokata K., Wakai K., Ohno Y.et al. Prognostic value of performance status assessed by patients themselves, nurses and oncologists in advanced non-small cell lung cancer. Br J Cancer. 85(11):2001;1634-1639.
8. Silvestri G., Pritchard R., Welch H.G. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ. 317:1998;771-775.
9. Fossella F. Docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer (NSCLC). Eur J Cancer. 37(suppl 6):2001;S154. abs 562.
10. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst. 91:1999;66-72.
11. Frasci G., Lorusso V., Panza N., Comella P., Nicolella G., Bianco A.et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol. 18:2000;2529-2536.
12. Rosell R., Gatzemeier U., Betticher D.C., Keppler U., Macha H.N., Pirker R.et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small cell lung cancer: a cooperative multinational trial. Ann Oncol. 13:2002;1539-1549.
13. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised trials. BMJ. 311:1995;899-909.
14. Soria J.-C., Brisgand D., Le Chevalier T. Do all patients with advanced non-small cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol. 12:2001;1667-1670.
15. Billingham L.J., Cullen M.H. The benefits of chemotherapy in patient subgroups with unresectable non-small cell lung cancer. Ann Oncol. 12:2001;1671-1675.
16. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J.et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 346:2002;92-98.
17. Sweeney C.J., Zhu J., Sandler A.B., Schiller J., Belani C.P., Langer C. et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic non-small cell lung carcinoma. Cancer. 92:2001;2639-2647.
18. Stephens R.J., Girling D.J., Machin D. Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified? Lung Cancer. 11:1994;259-274.
19. Side effects of specific cancer drugs. Available at: http://www. cancerhelp.org.uk/help/default.asp?page-177. Accessed November 10, 2003.
20. Souquet P.J., Tan E.H., Rodriguez Pereira J., van Klaveren R., Price A., Gatzemeier U.et al. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small cell lung cancer patients. Ann Oncol. 13:2002;1853-1861.
21. Hopwood P., Stephens R.J. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. Br J Cancer. 71:1995;633-636.
22. Macbeth F.R., Bolger J.J., Hopwood P., Bleehen N.M., Cartmell J., Girling D.J.et al. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Clin Oncol. 8(3):1996;167-175.
23. Stephens R.J., Hopwood P., Girling D.J. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer. 79:1999;538-544.
24. Muers M.F., Round C.E. Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax. 48:1993;339-343.
25. Vansteenkiste J., Vandebroek J., Nackaerts K., Dooms C., Galdermans D., Bosquee L.et al. Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. Lung Cancer. 40:2003;191-199.
26. Jaakkimainen L., Goodwin P.J., Pater J.et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomised trial of non-small cell lung cancer. J Clin Oncol. 8:1990;1301-1309.
27. Gatzemeier U., van Pawel J., Gottfried M., ten Velde G.P.M., Mattson K., DeMarinis F.et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small lung cancer. J Clin Oncol. 18:2000;3390-3399.
28. Herndon J.E., Fleishman S., Kosty M.P., Green M.R. A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. Control Clin Trials. 18:1997;286-300.
29. Anderson H., Hopwood P., Stephens R.J., Thatcher N., Cottier B., Nicolson M.et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomised trial with quality of life as the primary endpoint. Br J Cancer. 83:2000;447-453.
30. Berthelot J.-M., Will B.P., Evans W.K., Coyle D., Earle C.C., Bordeleau L. Decision framework for chemotherapeutic interventions for metastatic non-small cell lung cancer. J Natl Cancer Inst. 92:2000;1321-1329.
31. Evans W.K., Le Chevalier T. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. Eur J Cancer. 32A:1996;2249-2255.
32. Maher E.J., Coia L., Duncan G., Lawton P.A. Treatment strategies in advanced and metastatic cancer: differences in attitude between the USA, Canada and Europe. Int J Radiat Oncol Biol Phys. 23(1):1992;239-244.
33. Abratt R.P., Shepherd L.J., Salton D.G. Palliative radiation for stage 3 non-small cell lung cancer-a prospective study of two moderately high dose regimens. Lung Cancer. 13(2):1995;137-143.
34. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer. 63(2):1991;265-270.
35. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br J Cancer. 65(6):1992;934-941.
36. Bezjak A., Dixon P., Brundage M., Tu D., Palmer M.J., Blood P.et al. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys. 54(3):2002;719-728.
37. Nestle U., Nieder C., Walter K., Abel U., Ukena D., Sybrecht G.W.et al. A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 Gy: results of a randomized equivalence study. Int J Radiat Oncol Biol Phys. 48(1):2000;95-103.
38. Rees G.J., Devrell C.E., Barley V.L., Newman H.F. Palliative radiotherapy for lung cancer: two versus five fractions. Clin Oncol (R Coll Radiol). 9(2):1997;90-95.
39. Reinfuss M., Glinski B., Kowalska T., Kulpa J., Zawila K., Reinfuss K.et al. Radiotherapy for stage III, inoperable, asymptomatic small cell lung cancer. Final results of a prospective randomized study (240 patients). Cancer Radiother. 3(6):1999;475-479.
40. Simpson J.R., Francis M.E., Perez-Tamayo R., Marks R.D., Rao D.V. Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial. Int J Radiat Oncol Biol Phys. 11(4):1985;751-758.
41. Teo P., Tai T.H., Choy D., Tsui K.H. A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 14(5):1988;867-871.
42. Gaze M.N., Kerr G.R., MacDougall R.H., Howard G.C.W., Cowie V.J., Price A.et al. Improved symptom relief with fractionated palliative radiotherapy in patients with lung cancer [abs 3.8]. Br J Cancer. 85(Suppl 1):2001;18.
43. Sundstrom S., Bremnes R.M., Aasebo U., Hatlevoll R., Johannessen D.C., Brunsvig P.et al. Effect of hypofractionated palliative radiotherapy (17Gy/2 fractions) is comparable with standard fractionation in advanced non-small cell lung cancer [abs 1198]. Proc Am Soc Clin Oncol. 21:2002;300a.
44. Senkus-Konefka E., Jassem J., Bednaruk-Mlynski E., Dziadziuszko R., Kubrak J., Lewandowska A.et al. A prospective randomized study to compare the value of two fractionation schedules of palliative radiotherapy (RT) for inoperable non-small cell lung cancer (NSCLC). Eur J Cancer. 37(Suppl 6):2001;S52. Abstract 180.
45. Macbeth F.R., Wheldon T., Stephens R., Machin D. Radiation myelopathy: estimates of risks in three randomized trials of palliative radiotherapy for non-small cell lung cancer. Clin Oncol. 8:1996;176-181.
46. Dardoufas C., Platanoitis G.A., Damatopolou A., Kouvaris J., Vlahos L. A case of radiation myelopathy after 2×8.5Gy for inoperable non-small cell lung cancer. Eur J Cancer. 31A:1995;2418-2419.
47. Stevens M.J., Begbie S.D. Hypofractionated irradiation for inoperable non-small cell lung cancer. Aust Radiol. 39:1995;265-270.
48. Vyas R.K., Suryanarana U., Dixit S., Singhal S., Bhavasar D.C., Neema J.P.et al. Inoperable non-small cell lung cancer: palliative radiotherapy with two weekly fractions. Indian J Chest Dis Allied Sci. 40:1998;171-174.
49. Lupatelli M., Maranzo E., Bellavita R., Chionne F., Darwish S., Piro F. et al. Short course palliative radiotherapy in non-small cell lung cancer. Am J Clin Oncol. 23:2000;83-93.
50. Falk S.J., Girling D.J., White R.J., Hopwood P., Harvey A., Qian W.et al. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ. 325:2002;465-468.